Metagenomi TherapeuticsMGX +0.79%10 EBIT per Share is $-2.48 as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,172 Biotechnology companies, Metagenomi Therapeutics ranks worse than 86.77% on this metric.
Metagenomi Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.65.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.48.
During the past 3 years, the average EBIT per Share Growth Rate was -20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Metagenomi Therapeutics's EBIT per Share or its related term are showing as below:
MGX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.9 Med: -34.95 Max: -20
Current: -20
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Metagenomi Therapeutics was -20.00% per year. The lowest was -49.90% per year. And the median was -34.95% per year.
MGX's 3-Year EBIT Growth Rate is ranked worse than 86.77% of 1172
companies
in the Biotechnology industry
Industry Median: 15.4
vs MGX: -20.00
Metagenomi Therapeutics (NAS:MGX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Metagenomi Therapeutics EBIT per Share Related Terms
Metagenomi Therapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a EBIT per Share of $-2.48 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Metagenomi Therapeutics and its competitors. According to the industry distribution chart, Metagenomi Therapeutics ranks #1017 out of 1172 companies in the Biotechnology industry, placing it in the top 86.8%.
Is Metagenomi Therapeutics' EBIT per Share too high?
Metagenomi Therapeutics' current EBIT per Share is $-2.48. Based on the distribution chart, Metagenomi Therapeutics ranks #1017 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' EBIT per Share compare to KALA and HYPD?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #1017 out of 1172 companies for EBIT per Share. This places Metagenomi Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Metagenomi Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metagenomi Therapeutics's current EBIT per Share is $-2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current EBIT per Share of $-2.48. The current EBIT per Share is $-2.48. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current EBIT per Share is $-2.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
